Related Experiment Video

Updated: May 15, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Recent developments in oncolytic adenovirus-based immunotherapeutic agents for use against metastatic cancers

I-K Choi1, C-O Yun

  • 1Department of Bioengineering, College of Engineering, Hanyang University, Seoul, Korea.

Cancer Gene Therapy
|January 12, 2013
PubMed

Insights

Oncolytic adenoviruses (Ads) show promise for cancer treatment but require enhancement for efficacy. Genetically engineered Ads expressing immunostimulatory genes can induce systemic immunity, eradicating primary and metastatic tumors.

Area of Science:

  • Oncology
  • Gene Therapy
  • Immunotherapy
  • Virotherapy

Background:

  • Recurrent or metastatic cancers are largely incurable, necessitating novel treatment strategies.
  • Oncolytic adenoviruses (Ads) are promising virotherapeutic agents with a good safety profile.
  • Current limitations of oncolytic Ads include insufficient efficacy, local administration, immunological barriers, and poor tumor targeting.

Purpose of the Study:

  • To review recent advancements in developing potent oncolytic Ad-based immunotherapeutics.
  • To explore strategies for overcoming limitations of oncolytic Ads for treating primary and metastatic cancers.
  • To highlight the potential of oncolytic Ads in cancer gene therapy.

Main Methods:

  • Rational design of oncolytic Ads to express immunostimulatory genes.
  • Evaluation of local viral delivery strategies.
  • Investigation of combination therapies, including dendritic cell vaccines and radiotherapy.

Main Results:

  • Oncolytic Ad-based immunotherapeutics induce systemic antitumor immunity.
  • Local administration of engineered Ads can lead to the eradication of primary and metastatic tumors.
  • Combination therapies further enhance systemic tumor-specific immunity and suppress tumor growth.

Conclusions:

  • Engineered oncolytic adenoviruses represent a viable approach for effective cancer gene therapy.
  • Immunostimulatory gene expression enhances the systemic antitumor activity of oncolytic Ads.
  • Combination strategies show significant potential for complete tumor suppression.

More Related Videos

Ex Vivo Infection of Live Tissue with Oncolytic Viruses12:08

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

Production of High-Titer Recombinant Newcastle Disease Virus from Allantoic Fluid07:24

Production of High-Titer Recombinant Newcastle Disease Virus from Allantoic Fluid

Published on: May 25, 2022

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...